Cover Image
市場調查報告書

生物性骨材、Osteobiologics:全球產業、市場分析

Ortho and Osteobiologics: World Industry and Market Analysis 2014-2024

出版商 Visiongain Ltd 商品編碼 294348
出版日期 內容資訊 英文 195 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物性骨材、Osteobiologics:全球產業、市場分析 Ortho and Osteobiologics: World Industry and Market Analysis 2014-2024
出版日期: 2014年01月27日 內容資訊: 英文 195 Pages
簡介

全球生物性骨材市場預計2018年達到45億6,100萬美元。

本報告提供全球生物性骨材、Osteobiologics市場相關研究、市場趨勢、市場成長促進與阻礙因素彙整、各地區與主要各國的市場預測,再加上主要企業簡介等彙整資料,為您概述為以下內容。

第1章 摘要整理

第2章 生物性骨材的簡介

  • 生物性骨材是什麼?
  • 生物性骨材的分類法為何?
  • 成骨細胞在骨折治療中很重要
  • 自體移植片:「有代表性」骨移植片
  • 異體移植片:最基本的生物性骨材
  • 機器加工骨:定做移植的作成
  • 去礦物質骨基質(DBM):原始骨誘導生物性骨材
  • 促使組織形成的成長因素、信號
  • 幹細胞:生物性骨材的未來
  • 生物性骨材的法規
  • 骨質疏鬆症:潛伏的殺手
  • 從雙磷酸鹽(骨吸收抑制劑)到抗體:改善骨質密度的治療
  • 骨質疏鬆症的生物學治療方法:剛市售的單株抗體

第3章 生物性骨材:全球市場

  • 整形外科設備:290億美元以上的市場價值
  • 生物性骨材
  • 最急速成長的市場區隔為何?生物性骨材市場預測的明細
  • 引導生物性骨材市場的幹細胞治療
  • 下降的成長因素為何?

第4章 各地各國市場

  • 美國、日本重要的各國市場:生物性骨材市場各地區分析
  • 日本、德國擴大9%市場佔有率
  • 金磚四國擴大38%市場佔有率
  • 各國的生物性骨材市場分析
  • 美國
  • EU5個國家
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 日本
  • 金磚四國
  • 中國
  • 巴西
  • 印度
  • 俄羅斯
  • 其他

第5章 骨質疏鬆症的生物學治療方法:市場

  • 生技藥品獲得骨質疏鬆症市場21.9%
  • 主要的生技藥品品牌
  • Forteo在市場擴展
  • 生技藥品的急速成長:全球市場預測
  • 產品銷售額預測
  • 生物性骨材市場各國分析
  • 歐洲的重要性低
  • 美國
  • 歐洲的市場佔有率以10年以上減少到27%
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 日本
  • 金磚四國
  • 中國
  • 巴西
  • 印度
  • 俄羅斯
  • 其他

第6章 生物性骨材的研發產品線

  • 生物性骨材的生醫材料開發平台
  • 生技藥品骨質疏鬆症開發平台

第7章 生物性骨材市場主要企業

第8章 生物性骨材市場定量分析

  • 優勢和機會
  • 優勢
  • 弱點
  • 機會
  • 生物性骨材市場上的機會及威脅
  • 機會
  • 威脅
  • STEP分析
  • 技術要素
  • 政治要素

第9章 調查採訪

第10章 結論

圖表

目錄

Biotechnology for bone disorders - new study showing you trends, R&D progress, and predicted revenues

What's the future of orthobiologics and osteobiologics? Visiongain's updated report gives you predictions for those medical devices and pharmaceuticals. There you explore sales results, technologies, needs, R&D, opportunities, and revenue forecasts.

So see what's possible for those bone-repairing agents and related biotechnologies for bone diseases. You gain data and financial analysis for that industry. There find technological progress and commercial prospects for technology and medicines. Discover potential gains.

Read on to explore those treatments and see what their future market could be worth.

Forecasts and other analyses of technology for healing damaged bones

Orthobiologics constitute products using biology or biochemistry to treat musculoskeletal disorders. Sales of those drugs and other reconstructive therapies expand.

Our report covers two main segments: bone graft substitutes and biological treatments for osteoporosis. It then analyses components of those submarkets.

That new study gives you sales predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies in bone repair. There find potentials, hearing how you can gain.

Besides forecasting revenues to 2024, that work shows you historical results, growth rates, and market shares. There you explore technologies, applications, and developments (R&D). You also gain 64 tables, 60 charts, and two interviews with other authorities.

Knowledge to benefit your work and save time, helping your influence

Ever had trouble finding data you need? See in our report how you could help your business research, analyses, and decisions on treatments for debilitating bone conditions. Save time too. Also benefit your authority through better understanding the present and future.

So the following sections explain what you get in our new investigation.

Forecasting of that world market and its main segments - you explore possibilities

What're the secrets of that industry's progress? Where lies potential in treating bone disorders? Discover in our work overall world revenue to 2024 for orthobiologics and biologics for osteoporosis.

Also in that report you find individual revenue predictions to 2024 for six therapeutic submarkets at world level for orthobiologics:

  • Machined bone allografts
  • Demineralised bone matrices
  • Recombinant growth factors
  • Bone substitutes
  • Stem-cell therapies
  • Allograft implants.

There you assess outlooks for sales growth, seeing where you can gain.

So you explore competition and rising sales for products in orthopaedics (orthopedics), and related technology for rebuilding bones, including biological drugs (biologics). You get feel for that sector and its potential.

Discover the lucrative, expanding possibilities there. You also assess top products' futures.

Predictions of leading osteopathic agents' revenues

Find sales outlooks for brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for products, marketed and expected:

  • INFUSE
  • Prolia
  • Forteo
  • Preotact
  • Romosozumab
  • Biosimilars (follow-on biologics) for osteoporosis, grouped analysis.

There you find products and years with highest predicted sales and growth. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and sales potentials. See where you could profit.

Our work also divides its overall predictions into geographical regions.

Healthcare in leading national markets - what outlooks for those medical sales?

In developed and developing countries, opportunities for providers of bone treatments will increase from 2014 to 2024. See where and how, finding sales potentials for therapeutics.

Separately for orthobiologics and biologics for osteoporosis, our analyses show you individual revenue forecasts to 2024 for 11 national markets:

  • United States (US)
  • Japan
  • EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
  • BRIC nations - Brazil, Russia, India, and China.

There you find countries with highest revenues, demand, and potential revenue growth. Our work explains. You assess needs and demands for that specialist medicine.

Explore, too, how that biomedical and biopharma technology benefits developers, producers, marketers, and sellers. Our work shows you, discussing trends and needs.

Events and forces for developing, producing, marketing, and selling those bone medicines

Our report shows you issues and events affecting that biomedical and pharmaceutical sector from 2014, including these:

  • Bisphosphonates to monoclonal antibodies (mAbs) - therapies to improve bone density
  • Bone graft substitutes, orthopaedic devices and biologics suiting minimally-invasive surgery, inc. orthopaedic biomaterials
  • Stem cell therapies and Map3 and i-Factor bone grafts
  • Expanding markets for bone therapy, including effect of demographics on demand
  • Research and development (R&D) pipelines, inc. donor cell therapy, tibia fusing, spinal fusion, mimetic peptides, romosozumab, and blosozumab.

So you explore political, economic, social, and technological questions for treating bone disorders, investigating outlooks for commerce. Discover what the future holds.

Examine, then, what stimulates and restrains players in that industry, and affects its results.

Companies and 2018 market value - find prospects for success

What happens next? From 2014 novel treatments and regulations there encourage investments, medical advances, and higher revenues.

So our study predicts the world market for orthobiologics will reach $4,561m in 2018. There big pharma and specialty companies can gain, expanding business. Explore how and where.

And there you examine activities of many organisations, including these participants:

  • Eli Lilly
  • Amgen
  • Medtronic
  • Johnson & Johnson (DePuy Synthes)
  • NuVasive.

Also these firms, among others:

  • Baxter International
  • Biomet
  • Zimmer
  • RTI Biologics.

R&D for treating bone damage holds advantages, and from 2014 there will arise many opportunities. From this decade, patients, payers, and producing companies will benefit.

And you discover how those market segments can perform, staying ahead in knowledge.

Ways Ortho and Osteobiologics: World Industry and Market Analysis 2014-2024 helps

In particular, that new investigation gives you these advantages:

  • Revenues there to 2024 at world level, for 7 submarkets, and 5 products - examine outlooks for production, marketing, and sales
  • Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - assess developed and developing countries for potential revenues
  • Prospects for established competitors, emerging companies, and new entrants - explore portfolios, results, strategies, successes, and developmental activities.

Information found nowhere else, helping your searches, analyses, and plans

Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. Explore the business possibilities.

With our data you're less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find how you could save time and effort with our study, helping your planning, decisions, and authority.

Predictions for bone-healing technologies and products - gain now by trying our report

Our new report is for everyone investigating bone therapy - drugs and other solutions. There find commercial projections to help your work. So avoid missing out - please order now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Executive Summary

  • 1.1. Overview of Findings
  • 1.2. Aims and Coverage of this Report
  • 1.3. Structure of this Report
  • 1.4. Research and Analysis Methods
  • 1.5. Terms Related to This Report

2. Introduction to Orthobiologics

  • 2.1. What Are Orthobiologics?
  • 2.2. How Do we Classify Orthobiologics?
  • 2.3. Osteoblasts are Critical in Bone Healing
  • 2.4. Autografts - The "Gold Standard" Bone Graft
  • 2.5. Allografts- The Most Basic of Orthobiologics
  • 2.6. Machined Bones- Creating Customised Implants
  • 2.7. Demineralised Bone Matrix (DBM) - The Original Osteoinductive Orthobiologic
  • 2.8. Growth Factors, the Signals That Encourage Tissue Formation
    • 2.8.1. Bone Morphogenetic Proteins (BMPs) - Supercharging Osteoinduction
  • 2.9. Stem Cells - The Future of Orthobiology
  • 2.10. Regulation of Orthobiologics
    • 2.10.1. The US Approval and Regulation System
    • 2.10.2. The EU Approval and Regulation System
  • 2.11. Osteoporosis - The Insidious Killer
  • 2.12. From Bisphosphonates to Antibodies - Therapies to Improve Bone Density
  • 2.13. Biological Treatments for Osteoporosis - Monoclonal Antibodies Just Hitting the Market

3. Orthobiologics: Global Market, 2014-2024

  • 3.1. Orthopaedic Devices: Worth More Than $29bn in 2012
  • 3.2. Orthobiologics in 2012, a Diverse Multi-Billion Dollar Market
    • 3.2.1. Trends in Orthobiologics, 2012
  • 3.3. Which Segments Will Grow Fastest? Orthobiologics Market Forecast Breakdown, 2014-2024
    • 3.3.1. Steady Growth in Machined Bones, 2014-2024
    • 3.3.2. Growth Spurt in Demineralised Bone Matrices, 2014-2024
    • 3.3.3. Declining Growth Factor Sales, 2014-2024
    • 3.3.4. Accelerated Growth for Bone Substitutes, 2013-2024
    • 3.3.5. Sustained High Growth for Stem-Cells Therapies, 2014-2024
    • 3.3.6. Allograft Market Remains Small, 2014-2024
  • 3.4. Stem-Cell Therapies will lead the Orthobiologics Market
    • 3.4.1. Stem-Cell Therapies: Drivers and Restraints
    • 3.4.2. The Only Osteogenic Bone Graft Substitute
    • 3.4.3. Better than Autograft
    • 3.4.4. Treating at Risk Patients
    • 3.4.5. What is the Alternative?
    • 3.4.6. High Costs Limit Access
    • 3.4.7. Where is the Clinical Evidence?
    • 3.4.8. Human Tissue or Biological Product?
  • 3.5. Growth Factors Fall From Grace
    • 3.5.1. Growth Factor Products: Drivers and Restraints
    • 3.5.2. Autograft Equivalence
    • 3.5.3. Surgeons Still like INFUSE
    • 3.5.4. Off-label Adverse Events
    • 3.5.5. High Unit Cost
    • 3.5.6. Stem-Cell Competition

4. Regional and National Markets, 2014-2024

  • 4.1. US and Japan are Crucial National Markets - Regional Breakdown of the Orthobiologics Market, 2012
  • 4.2. Japan and Germany Increase Market Share by 9%: National Markets, 2012-2018
  • 4.3. BRIC Countries Increase Market Share by 38%: National Markets, 2018-2024
  • 4.4. National Orthobiologic Market Analysis, 2014-2024
  • 4.5. The US Remains Fundamental to Growth: Market Forecast, 2014-2024
    • 4.5.1. Demographics, Drivers and Restraints
  • 4.6. Steady Growth for Orthobiologics in the Five Leading European Nations, 2014-2024
    • 4.6.1. Demographics, Drivers, and Restraints
  • 4.7. Germany Leads Europe: Market Forecast, 2014-2024
    • 4.7.1. Demographics, Drivers, and Restraints
  • 4.8. Expanding Orthobiologics in the UK: Market Forecast, 2014-2024
    • 4.8.1. Demographics, Drivers, and Restraints
  • 4.9. Slow Growth in the French Orthobiologics: Market Forecast, 2014-2024
    • 4.9.1. Demographics, Drivers, and Restraints
  • 4.10. Stuttering Growth for Orthobiologics in Italy: Market Forecast, 2014-2024
  • 4.11. Dwindling Demand in Spain: Market Forecast, 2014-2024
  • 4.12. The Rise of Orthobiologics in Japan: Market Forecast, 2014-2024
    • 4.12.1. Demographics, Drivers, and Restraints
  • 4.13. BRIC Nations to Increase Market Share by 42%: Regional Market Forecast, 2014-2024
  • 4.14. China, the Principal Emerging Nation: Market Forecast, 2014-2024
    • 4.14.1. Demographics, Drivers, and Restraints
  • 4.15 Explosive Growth in Brazilian Orthobiologics: Market Forecast, 2014-2024
    • 4.15.1 Demographics, Drivers, and Restraints
  • 4.16. Too Soon for Orthobiologics in India: Market Forecast, 2014-2024?
  • 4.17. Tepid Growth in Russian Orthobiologics: Market Forecast, 2014-2024
    • 4.17.1. Demographics, Drivers, and Restraints
  • 4.18. Orthobiologics in Minor Nations: Market Forecast, 2014-2024

5. Biological Treatments for Osteoporosis: Market to 2024

  • 5.1. Biologics Take 21.9% of the Osteoporosis Market in 2012
  • 5.2. Leading Biologic Brands
    • 5.2.1. Prolia (Denosumab; Amgen)
    • 5.2.2. Forteo (Teriparatide; Eli Lilly)
    • 5.2.3. Preotact (Recombinant Parathyroid Hormone; NPS Pharmaceuticals)
  • 5.3. Forteo Spearheads the Market in 2012
  • 5.4. Rapid Growth for Biologics: Global Market Forecast, 2014-2024
  • 5.5. Forecasted Product Sales, 2014-2024
    • 5.5.1. Prolia to Drive the Market
    • 5.5.2. Forteo Loses Market Share
  • 5.6. National Breakdown of the Osteobiologics Market, 2012
  • 5.7. Declining Importance of Europe: Forecasted National Markets 2014-2024
  • 5.8. US Dictates Growth: Market Forecast, 2014-2024
    • 5.8.1. Demographics, Drivers, and Restraints
  • 5.9. European Market Share to Decline by 27% Over Ten Years
  • 5.10. German Market to Plateau: Market Forecast 2014-2024
    • 5.10.1. Demographics, Drivers, and Restraints
  • 5.11. Revenue Ceiling in the UK: Market Forecast 2014-2024
    • 5.11.1. Demographics, Drivers, and Restraints
  • 5.12. French Market to Double in Five Years: Market Forecast 2014-2024
    • 5.12.1. Demographics, Drivers, and Restraints
  • 5.13. Price Controls Restrict Italian Growth: Market Forecast 2014-2024
    • 5.13.1. Demographics, Drivers, and Restraints
  • 5.14. Limited Expansion in Spain: Market Forecast 2014-2024
    • 5.14.1. Demographics, Drivers, and Restraints
  • 5.15. Continual Growth in Japan: Market Forecast 2014-2024
    • 5.15.1. Demographics, Drivers, and Restraints
  • 5.16. BRIC Nations to Treble in Value in Less Than Ten Years
  • 5.17 China Increases Market Share by 48%: Market Forecast 2014-2024
    • 5.17.1 Demographics, Drivers, and Restraints
  • 5.18. Brazil Set to Expand by 185%: Market Forecast, 2014-2024
    • 5.18.1. Demographics, Drivers, and Restraints
  • 5.19. Strong Growth but Poor Value in India: Market Forecast 2014-2024
    • 5.19.1. Demographics, Drivers, and Restraints
  • 5.20. Limited Value in Russia: Market Forecast 2014-2024
    • 5.20.1. Demographics, Drivers, and Restraints
  • 5.21. Minor National Markets Forecast, 2014-2024

6. R&D Pipeline for Orthobiologics

  • 6.1. Orthobiologic Biomaterials Pipeline
    • 6.1.1. i-FACTOR (Cerapedics) - Osteoinduction Without Hazardous Growth Factors
    • 6.1.2. Bone Therapeutics, Focussed on Cell Therapies
  • 6.1.2.1. PREOB - Leading Candidate For Non-Union and Osteoporosis
  • 6.1.2.2. ALLOB - Early Stage Donor Cell Therapy
    • 6.1.3. Map3 (RTI Biologics) - Competition for Osteocel and Trinity Evolution
    • 6.1.4. NeoFuse (Mesoblast) - Comparable to the "Gold Standard"
    • 6.1.5. Kuros Biosurgery - Partnered With Synthes to Develop Orthobiologics
      • 6.1.5.1. KUR-111 - An Alternative to Autograft for Fusing the Tibia
      • 6.1.5.2. KUR-113 - Another Parathyroid Hormone for Tibia Fractures
      • 6.1.5.3. KUR-115 - About to Enter Phase II Trials for Spinal Fusion
    • 6.1.6. Amplex (BioSET) - A Mimetic Peptide for BMP-2
    • 6.1.7. UCB-1 (Nell-1; Bone Biologics) - Early Stage Protein with Sclerostin like Potential
  • 6.2. Biological Osteoporosis Pipeline
    • 6.2.1. Romosozumab (AMG 785) - Blockbuster in Waiting
    • 6.2.2. Blosozumab (LY2541546) - Second in Class Sclerostin Antibody
    • 6.2.3. ZP-PTH - Parathyroid by Way Micro Needle Patch
    • 6.2.4. ZT-034 - Will Need More Than Biomarkers for Approval
    • 6.2.5. BA058 - Looking to Compete With Forteo

7. Leading Companies in the Orthobiologics Market, 2013-2014

  • 7.1. Domination of Medtronic and Johnson & Johnson
  • 7.2. Leading Companies in the Orthobiologics Market, 2013
  • 7.3. Medtronic
    • 7.3.1. INFUSE Sales Results
  • 7.4. Johnson & Johnson (DePuy Synthes), Dominant in the Orthobiologics and Medical Device Market
  • 7.5. Vitoss Crucial to Stryker Sales
  • 7.6. Integra LifeSciences, Looking to Innovation with Accell DBMs
  • 7.7. NuVasive - The Leading Force in the Stem Cell Market
  • 7.8. RTI Biologics, Producing the Full Spectrum of Orthobiologics
  • 7.9. Baxter International, Acquiring Its Way into the Market
  • 7.10. Biomet - Big in Orthopaedics, Building Up in Orthobiologics
  • 7.11. Wright Medical, Shifting Focus into the Ankle Market
  • 7.12. Globus Medical- The Fastest Growing Orthopaedics Company
  • 7.13. Zimmer Spine, Weak Sales for a Multinational Powerhouse
  • 7.14. Bacterin - Exclusively Biological Business Model
  • 7.15. Olympus Biotech, Focussed on Minimally Invasive Surgery
  • 7.16. Fragmented Market for Smaller Companies
  • 7.17. Shift to High Margin Products and Specialisation

8. Qualitative Analysis of the Orthobiologics Market, 2014

  • 8.1. Strengths and Weaknesses of the Orthobiologics Market
  • 8.2. Strengths
    • 8.2.1. Eli Lilly and Amgen Dominate the Biological Osteoporosis Market
    • 8.2.2. Biologics Suit Minimally Invasive Surgery
    • 8.2.3. Patients Stick to Biologics
  • 8.3. Weaknesses
    • 8.3.1. Intense Competition in the Biomaterials Market
    • 8.3.2. Are Biologics Worth the Bill?
    • 8.3.3. Soaring Clinical Development Costs
    • 8.3.4. The Silent Disease
  • 8.4. Opportunities and Threats in the Orthobiologics Market
  • 8.5. Opportunities
    • 8.5.1. Increase Diagnosis Rates to Increase Sales
    • 8.5.2. Beat the Best in Class
    • 8.5.3. Access to the Surgical Community
    • 8.5.4. Replacing Autografts
  • 8.6. Threats
    • 8.6.1. Generic Bisphosphonate Competition
    • 8.6.2. Getting Paid in the US and Europe
    • 8.6.3. Accessing the Asian Markets
    • 8.6.4. Treatment Only as a Last Resort
  • 8.7. Social, Technological, Economic, and Political (STEP) Analysis
    • 8.7.1. Social Factors
    • 8.7.2. Ageing Populations in the Developed and BRIC Nations
    • 8.7.3. Unhealthy Lifestyles and the Global rise in Prevalence of Diabetes
  • 8.8. Technological Factors
    • 8.8.1. Harnessing Stem Cell and Gene Based Therapies
  • 8.9. Economic Factors
    • 8.9.1. Reimbursement and Cost Cutting in the Europe and the US
    • 8.9.2. Free Trade within the European Union, Parallel Trade and Arbitrage
    • 8.9.3. Record Low Cost of Borrowing - What Happens When the Music's Over?
  • 8.10. Political Factors
    • 8.10.1. The Patient Protection and Affordable Care Act in the US

9. Research Interviews

  • 9.1. Interview with an Executive at an International Orthobiologics Company
    • 9.1.1. Matching Products to Patients at Risk
    • 9.1.2. Demanding Clinical and Economic Evidence
    • 9.1.3. Stem Cells are Critical
    • 9.1.4. Developed Markets and Latin America Drive Growth
    • 9.1.5. Too Early for China?
    • 9.1.6. Moving Away From Basic Bone Substitutes
    • 9.1.7. Medical Education is Crucial
    • 9.1.8. Safety and Efficacy of BMP Products
  • 9.2. Interview with Dr Nancy Epstein M.D., Chief of Neurosurgical and Spine Education, Winthrop University Hospital
    • 9.2.1. INFUSE to be taken off the Market
    • 9.2.2. An "Off-label" Product NOT Approved by the Food and Drug Administration
    • 9.2.3. Surgeons Still Demand Innovation for Patients at Risk
    • 9.2.4. Gene Therapy

10. Conclusions

  • 10.1. Continued Growth in Orthobiologics
    • 10.1.1. Stem-Cell Products Dominate the Market
    • 10.1.2. Decline in Growth Factor Sales
    • 10.1.3. US Continues to Dominate the Market
  • 10.2. Biologics Break Osteoporosis
    • 10.2.1. Patient Population Explosion
    • 10.2.2. Prolia and Romosozumab Lead the Market
    • 10.2.3. Early Access to Japan

List of Tables

  • Table 2.1: Mechanisms Involved in Bone Grafting
  • Table 3.1: Global Orthopaedic Device Market: Segment Revenue ($bn) and Market Share (%), 2012
  • Table 3.2: Global Orthobiologics Market: Segment Revenue ($m) and Market Share (%), 2012
  • Table 3.3: Global Orthobiologics Market Forecasts: Segment Revenue ($m), Annual Growth Rate (%), Segment Market Share (%), CAGR (%), 2012-2018
  • Table 3.4: Global Orthobiologics Market Forecasts: Segment Revenue ($m), Annual Growth Rate (%), Segment Market Share (%), CAGR (%), 2018-2024
  • Table 3.5: Global Machined Bone Market Forecast: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
  • Table 3.6: Global Demineralised Bone Matrix Market Forecast: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
  • Table 3.7: Global Growth Factor Market Forecast: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
  • Table 3.8: Global Bone Substitute Market Forecast: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
  • Table 3.9: Global Stem Cell Therapy Market Forecast: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
  • Table 3.10: Global Allograft Bone Market Forecast: Revenue ($m) Annual Growth Rate (%), CAGR (%), 2013-2024
  • Table 3.11: INFUSE Revenue Forecast: Revenue ($m), Annual Growth Rate (%), Peak of Sales (%), CAGR (%), 2011-2024
  • Table 4.1: Global Orthobiologics Market: National Market Revenue ($m), Market Share (%), 2012
  • Table 4.2: Global Orthobiologic Market: National Market Revenue ($m), Market Share (%), 2018
  • Table 4.3: Global Orthobiologic Market: National Market Revenue ($m), Market Share (%), 2024
  • Table 4.4: Global Orthobiologics Market: Regional Revenue Forecasts ($m), Annual Growth (%), Global Market Share (%), CAGR (%), 2013-2018
  • Table 4.5: Global Orthobiologics Market: Regional Revenue Forecasts($m), Annual Growth (%), Global Market Share (%), CAGR (%), 2018-2024
  • Table 4.6: US Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 4.7: Five Leading European Orthobiologic Markets: National Revenue Forecasts ($m), Annual Growth Rate (%), European Market Share (%), CAGR (%), 2013-2018
  • Table 4.8: Five Leading European Orthobiologic Markets: National Revenue Forecasts ($m), Annual Growth Rate (%), European Market Share (%), CAGR (%), 2018-2024
  • Table 4.9: German Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 4.10: UK Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 4.11: French Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 4.12: Italian Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 4.13: Spanish Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 4.14: Japanese Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 4.15: BRIC Orthobiologic Markets: Revenue Forecasts ($m), Annual Growth (%), BRIC Market Share (%), CAGR (%), 2013-2018
  • Table 4.16: BRIC Orthobiologic Markets: Revenue Forecasts ($m), Annual Growth (%), BRIC Market Share (%), CAGR (%), 2018-2024
  • Table 4.17: Chinese Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 4.18: Brazilian Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 4.19: Indian Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 4.20: Russian Orthobiologic Market: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 4.21: Minor National Orthobiologic Markets: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 5.1: Global Osteoporosis Market: Segment Revenue ($m), Market Share (%), 2012
  • Table 5.2: Biologics Osteoporosis Treatments, Product Revenue ($m) and Market Share (%), 2012 and 2013
  • Table 5.3: Global Osteoporosis Biologics Market Forecast: Total Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
  • Table 5.4: Global Osteoporosis Biologics Market Forecasts: Product Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2018
  • Table 5.5: Global Osteoporosis Biologics Market Forecasts: Product Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2018-2024
  • Table 5.6: National Markets for Osteoporosis Biologics: Revenue ($m), Market Share (%), 2012
  • Table 5.7: Global Osteoporosis Biologics Market: Regional Revenue Forecasts ($m), Annual Growth (%), Global Market Share (%), CAGR (%), 2013-2018
  • Table 5.8: Global Osteoporosis Biologics Market: Regional Revenue Forecasts ($m), Annual Growth (%), Global Market Share (%), CAGR (%), 2018-2024
  • Table 5.9: US Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 5.10: Reported Costs of Biological Osteoporosis Treatments in the US and UK Markets, 2013
  • Table 5.11: Five Leading European Nationals Markets for Osteoporosis Biologics: Revenue Forecasts ($m), Annual Growth Rate (%), European Market Share (%), Global Market Share (%), CAGR (%), 2013-2018
  • Table 5.12: Five Leading European Nationals Markets for Osteoporosis Biologics: Revenue Forecasts ($m), Annual Growth Rate (%), European Market Share (%), Global Market Share (%), CAGR (%), 2018-2024
  • Table 5.13: German Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 5.14: UK Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 5.15: French Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 5.16: Italian Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 5.17: Spanish Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 5.18: Japanese Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 5.19: BRIC Markets for Osteoporosis Biologics: National Revenue Forecasts ($m), Annual Growth Rate (%), BRIC Market Share (%), Global Market Share (%), CAGR (%), 2013-2018
  • Table 5.20: BRIC Markets for Osteoporosis Biologics: National Revenue Forecasts ($m), Annual Growth Rate (%), BRIC Market Share (%), Global Market Share (%), CAGR (%), 2018-2024
  • Table 5.21: Chinese Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 5.22: Brazilian Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 5.23: Indian Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 5.24: Russian Market for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 5.25: Minor National Markets for Osteoporosis Biologics: Revenue ($m), Annual Growth Rate (%), Global Market Share (%), CAGR (%), 2013-2024
  • Table 6.1: Orthobiologic Biomaterials in Development, 2013
  • Table 6.2: Osteoporosis Biologics in Development, 2013
  • Table 7.1: Leading Orthobiologics Companies: Revenue ($m), Market Share (%), 2012
  • Table 7.2: INFUSE (rhBMP-2) Sales: Revenue ($m), Annual Growth Rate (%), Peak of Sales (%), CAGR, 2010-2014
  • Table 7.3: Smaller Orthobiologics Manufacturers: Listed A-E, 2013
  • Table 7.4: Smaller Orthobiologics Manufacturers: Listed G-T, 2013

List of Figures

  • Figure 3.1: Orthopaedic Devices Market: Segment Market Shares (%), 2012
  • Figure 3.2: Global Orthopaedics Biomaterials Market: Segment Market Shares (%), 2012
  • Figure 3.3: Segmented Orthobiologics Market Forecast: Segment Revenues ($m), 2013-2024
  • Figure 3.4: Total Global Orthobiologics Forecast: Revenue ($m), 2013-2024
  • Figure 3.5: Machined Bone Market Forecast: Revenue ($m), 2013-2024
  • Figure 3.6: Global Demineralised Bone Matrix Market Forecast: Revenue ($m), 2013-2024
  • Figure 3.7: Global Growth Factor Market Forecast: Revenue ($m),2013-2024
  • Figure 3.8: Global Bone Substitute Market Forecast: Revenue ($m), 2013-2024
  • Figure 3.9: Global Stem Cell Therapy Market Forecast: Revenue ($m), 2013-2024
  • Figure 3.10: Global Allograft Bone Market Forecast: Revenue ($m), 2013-2024
  • Figure 3.11: Stem-Cell Therapy Market: Drivers and Restraints, 2014-2024
  • Figure 3.12: INFUSE Revenue Forecast: Revenue ($m), 2013-2024
  • Figure 3.13: Growth Factor Market: Drivers and Restraints, 2014-2024
  • Figure 4.1: Global Orthobiologics Market: National Market Shares (%), 2012
  • Figure 4.2: Global Orthobiologic Market: National Market Shares (%), 2018
  • Figure 4.3: Global Orthobiologic Market: National Market Shares (%), 2024
  • Figure 4.4: Global Orthobiologics Market: Regional Revenues ($m), 2013-2024
  • Figure 4.5: US Orthobiologic Market: Revenue ($m), 2013-2024
  • Figure 4.6: Five Leading European Orthobiologic Markets: National Market Revenues ($m), 2013-2024
  • Figure 4.7: German Orthobiologic Market: Revenue ($m), 2013-2024
  • Figure 4.8: UK Orthobiologic Market: Revenue ($m), 2013-2024
  • Figure 4.9: French Orthobiologic Market: Revenue ($m), 2013-2024
  • Figure 4.10: Italian Orthobiologic Market: Revenue ($m), 2013-2024
  • Figure 4.11: Spanish Orthobiologic Market: Revenue ($m), 2013-2024
  • Figure 4.12: Japanese Orthobiologic Market: Revenue ($m), 2013-2024
  • Figure 4.13: BRIC Orthobiologic Markets: National Revenues ($m), 2013-2024
  • Figure 4.14: Chinese Orthobiologic Market: Revenue ($m), 2013-2024
  • Figure 4.15: Brazilian Orthobiologic Market: Revenue ($m), 2013-2024
  • Figure 4.16: Indian Orthobiologic Market: Revenue ($m), 2013-2024
  • Figure 4.17: Russian Orthobiologic Market: Revenue ($m), 2013-2024
  • Figure 4.18: Minor National Orthobiologic Market: Revenue ($m), 2013-2024
  • Figure 5.1: Global Osteoporosis Market, Segment Market Shares (%), 2012
  • Figure 5.2: Biologics Osteoporosis Treatments: Product Revenue ($m), 2012 and 2013
  • Figure 5.3: Global Osteoporosis Biologics Market Forecast: Total Revenue ($m), 2013-2024
  • Figure 5.4: Global Osteoporosis Biologics Market Forecast: Product Revenues ($m), 2013-2024
  • Figure 5.5: Global Prolia Market Forecast: Revenue ($m), 2013-2024
  • Figure 5.6: Global Forteo Market Forecast: Revenue ($m), 2013-2024
  • Figure 5.7: Global Preotact Market Forecast: Revenue ($m), 2013-2024
  • Figure 5.8: Global Romosozumab Market Forecast: Revenue ($m), 2013-2024
  • Figure 5.9: Global Generics Market: Revenue ($m), 2013-2024
  • Figure 5.10: National Markets for Osteoporosis Biologics: Market Shares (%), 2012
  • Figure 5.11: Global Osteoporosis Biologics Market: Regional Revenues ($m), 2013-2024
  • Figure 5.12: US Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
  • Figure 5.13: Five Leading European National Markets for Osteoporosis Biologics: Revenues ($m), 2013-2024
  • Figure 5.14: German Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
  • Figure 5.15: UK Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
  • Figure 5.16: French Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
  • Figure 5.17: Italian Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
  • Figure 5.18: Spanish Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
  • Figure 5.19: Japanese Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
  • Figure 5.20: BRIC Markets for Osteoporosis Biologics: Revenues ($m), 2013-2024
  • Figure 5.21: Chinese Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
  • Figure 5.22: Brazilian Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
  • Figure 5.23: Indian Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
  • Figure 5.24: Russian Market for Osteoporosis Biologics: Revenue ($m), 2013-2024
  • Figure 5.25: Minor National Markets for Osteoporosis Biologics: Revenue ($m), 2013-2024
  • Figure 7.1: Leading Orthobiologics Companies: Revenues ($m), 2012
  • Figure 7.2: INFUSE (rhBMP-2) Sales: Revenue ($m), 2010-2014
  • Figure 8.1: Orthobiologics Market: Strengths and Weaknesses, 2014-2024
  • Figure 8.2: Orthobiologics Market: Opportunities and Threats, 2014-2024

Companies Listed

  • AAP Implante
  • Allosource
  • Alphatec
  • Amgen
  • Angel Biotechnology
  • ApaTech
  • Arthrocare
  • Atheriocyte Medical Systems Inc
  • Athersys
  • Azelon Pharmaceuticals
  • Bacterin
  • Baxter
  • Berkeley Advanced Biomaterials Inc
  • Biocomposites
  • Biocoral
  • Biological Therapies
  • Biomatlante
  • Biomet
  • BioMimetic Therapeutics
  • BioSET
  • BioTissue
  • BonAlive Biomaterials
  • Bone Biologics
  • Bone Solutions
  • Bone Therapeutics
  • BoneSupport
  • Brazilian Unified Health System (SUS)
  • Cardium Therapeutics
  • Celltech
  • Centre for Devices and Radiological Health (CDRH)
  • Ceramisys
  • Cerapedics
  • co.don
  • Collagen Matrix
  • Curasan
  • Cytomedix
  • Daiichi Sankyo
  • DePuy Synthes
  • Eli Lilly
  • ETEX Corporation
  • European Medicines Agency (EMA)
  • European Union (EU)
  • Exactech
  • Fitch Ratings
  • Food and Drug Administration (FDA)
  • Forest Laboratories
  • Geistlich Biomaterials
  • German Institute for Quality and Efficiency in Healthcare (IQWiG)
  • GlaxoSmithKline (GSK)
  • Globus Medical
  • Graftys
  • Histogenics Corporation
  • Integra LifeSciences
  • ISTO Technologies
  • Johnson & Johnson
  • Kasios
  • Kensey Nash
  • Kinetic Concepts
  • Kuros Biosurgery
  • Lindare Medical
  • Medtronic
  • Merck & Co
  • Mesoblast
  • MicroPort Medical
  • MiMedx Group
  • Monet Medical
  • Musculoskeletal Transplant Foundation
  • National Health Service (NHS)
  • National Institute for Clinical Excellence (NICE)
  • NovaBone Products LLC
  • Novartis
  • NPS Pharmaceuticals
  • NuVasive
  • Nycomed
  • Olympus Biotech
  • Orteq Bioengineering
  • Orthofix
  • Orthovita
  • Osiris Therapeutics
  • OsteoGeneX
  • Osteotech
  • Parcell Laboratories
  • Pharma and Medical Devices Agency (PMDA)
  • Pioneer Surgical Technologies
  • PolyNovo Biomaterials
  • Progenteq
  • Radius Health
  • Roche
  • Royal DSM
  • RTI Biologics
  • Scorpion Medical
  • Spinal Restoration
  • SpineSmith Partners LP
  • State Food and Drug Administration (SFDA, China)
  • Stryker
  • Takeda
  • Teknimed
  • Teva Pharmaceutical Industries
  • Tigenix
  • Tissue Banks International
  • Tissue Genesis
  • TissueGene
  • Tornier
  • UCB
  • Winthrop University Hospital
  • World Health Organization (WHO)
  • Wright Medical
  • Yale University
  • Zimmer
  • Zosano Pharma
Back to Top